Open Access
Open access
volume 37 issue 12 pages 110143

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

M. Gordon Joyce 1, 2
Wei-Hung Chen 1, 3
Rajeshwer S. Sankhala 1, 3
Agnes Hajduczki 1, 3
Paul Thomas 1, 3
Misook Choe 1, 3
William C Chang 1, 3
Caroline E. Peterson 1, 3
Elaine B Morrison 4
Clayton S. Smith 5, 6
Rita P.-Y. Chen 7, 8, 9, 10
Aslaa Ahmed 11
Lindsay Wieczorek 4, 12
A S Anderson 13, 14
James Brett Case 7, 8, 9, 10
李艺凡 Li Yifan 4, 12
Therese Oertel 13, 14
Lorean Rosado 4, 12
Akshaya Ganesh 13, 14
Connor Whalen 13, 14
Joshua M Carmen 4
Letzibeth Mendez Rivera 4, 12
Christopher P Karch 4, 12
Neelakshi Gohain 4, 12
Zuzana Villar 4, 12
David McCurdy 4, 12
Zoltan Beck 4, 12
Jiae Kim 4, 12
Shikha Shrivastava 4, 12
Ousman Jobe 4, 12
Vincent Dussupt 4, 12
Sebastian Molnar 4, 12
Ursula Tran 4, 12
Chandrika B Kannadka 4, 12
Sandrine Soman 11
Caitlin Kuklis 11
Michelle Zemil 4, 12
Htet Khanh 5, 6
Wei-Min Wu 5, 6
Matthew Cole 15
Debra K. Duso 15
Larry W. Kummer 15
Tricia J Lang 15
Shania E Muncil 15
Shelly J. Krebs 4, 12
Saravanan Rajan 16
Patrick M Mctamney 17
Mark T Esser 17
William Reiley 15
Morgane Rolland 4, 12
Natalia de Val 5, 6
MICHAEL P. DIAMOND 7, 8, 9, 10
Mangala Rao 4
1
 
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA
2
 
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. Electronic address: gjoyce@eidresearch.org.
3
 
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
4
 
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
11
 
Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
12
 
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
13
 
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
15
 
Trudeau Institute, Inc., Saranac Lake, NY, USA.
16
 
Antibody Discovery and Protein Engineering (ADPE), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
17
 
Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
18
 
Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
19
 
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA. Electronic address: kayvon.modjarrad.civ@mail.mil.
Publication typeJournal Article
Publication date2021-12-08
scimago Q1
wos Q1
SJR3.796
CiteScore12.9
Impact factor6.9
ISSN22111247, 26391856
General Biochemistry, Genetics and Molecular Biology
Abstract

Summary

The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID50 > 10,000) following a single immunization, whereas RBD-ferritin nanoparticle (RFN) immunogens elicit similar responses after two immunizations and also show durable and potent neutralization against circulating VoCs. Passive transfer of immunoglobulin G (IgG) purified from SpFN- or RFN-immunized mice protects K18-hACE2 transgenic mice from a lethal SARS-CoV-2 challenge. Furthermore, S-domain nanoparticle immunization elicits ACE2-blocking activity and ID50 neutralizing antibody titers >2,000 against SARS-CoV-1, highlighting the broad response elicited by these immunogens.
Found 
Found 

Top-30

Journals

2
4
6
8
10
12
14
Vaccines
13 publications, 8.78%
bioRxiv
7 publications, 4.73%
Nature Communications
6 publications, 4.05%
Viruses
4 publications, 2.7%
Frontiers in Immunology
4 publications, 2.7%
Vaccine
4 publications, 2.7%
npj Vaccines
3 publications, 2.03%
International Journal of Biological Macromolecules
3 publications, 2.03%
Expert Review of Vaccines
3 publications, 2.03%
Cell
3 publications, 2.03%
Science advances
2 publications, 1.35%
Advanced healthcare materials
2 publications, 1.35%
International Journal of Molecular Sciences
2 publications, 1.35%
Signal Transduction and Targeted Therapy
2 publications, 1.35%
Journal of Medical Virology
2 publications, 1.35%
Journal of Virology
2 publications, 1.35%
The Lancet Microbe
2 publications, 1.35%
International Journal of Pharmaceutics
2 publications, 1.35%
iScience
2 publications, 1.35%
Nanoscale
2 publications, 1.35%
Microbial Drug Resistance
1 publication, 0.68%
Frontiers in Bioengineering and Biotechnology
1 publication, 0.68%
Nature Immunology
1 publication, 0.68%
Journal of Biomedical Science
1 publication, 0.68%
Experimental and Molecular Medicine
1 publication, 0.68%
Science China Life Sciences
1 publication, 0.68%
Cell Reports
1 publication, 0.68%
Process Biochemistry
1 publication, 0.68%
Biotechnology Advances
1 publication, 0.68%
2
4
6
8
10
12
14

Publishers

5
10
15
20
25
30
35
40
Elsevier
39 publications, 26.35%
Springer Nature
23 publications, 15.54%
MDPI
22 publications, 14.86%
Cold Spring Harbor Laboratory
19 publications, 12.84%
Wiley
9 publications, 6.08%
American Chemical Society (ACS)
9 publications, 6.08%
Frontiers Media S.A.
6 publications, 4.05%
Taylor & Francis
6 publications, 4.05%
Royal Society of Chemistry (RSC)
4 publications, 2.7%
American Association for the Advancement of Science (AAAS)
3 publications, 2.03%
American Society for Microbiology
3 publications, 2.03%
Mary Ann Liebert
2 publications, 1.35%
Public Library of Science (PLoS)
1 publication, 0.68%
The American Association of Immunologists
1 publication, 0.68%
Research Square Platform LLC
1 publication, 0.68%
5
10
15
20
25
30
35
40
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
148
Share
Cite this
GOST |
Cite this
GOST Copy
Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity // Cell Reports. 2021. Vol. 37. No. 12. p. 110143.
GOST all authors (up to 50) Copy
Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity // Cell Reports. 2021. Vol. 37. No. 12. p. 110143.
RIS |
Cite this
RIS
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Joyce,
author = {M. Gordon Joyce and Wei-Hung Chen and Rajeshwer S. Sankhala and Agnes Hajduczki and Paul Thomas and Misook Choe and Elizabeth J. Martinez and William C Chang and Caroline E. Peterson and Elaine B Morrison and Clayton S. Smith and Rita P.-Y. Chen and Aslaa Ahmed and Lindsay Wieczorek and A S Anderson and James Brett Case and 李艺凡 Li Yifan and Therese Oertel and Lorean Rosado and Akshaya Ganesh and Connor Whalen and Joshua M Carmen and Letzibeth Mendez Rivera and Christopher P Karch and Neelakshi Gohain and Zuzana Villar and David McCurdy and Zoltan Beck and Jiae Kim and Shikha Shrivastava and Ousman Jobe and Vincent Dussupt and Sebastian Molnar and Ursula Tran and Chandrika B Kannadka and Sandrine Soman and Caitlin Kuklis and Michelle Zemil and Htet Khanh and Wei-Min Wu and Matthew Cole and Debra K. Duso and Larry W. Kummer and Tricia J Lang and Shania E Muncil and Jeffrey R. Currier and Shelly J. Krebs and Victoria R Polonis and Saravanan Rajan and Patrick M Mctamney and others},
title = {SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity},
journal = {Cell Reports},
year = {2021},
volume = {37},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.celrep.2021.110143},
number = {12},
pages = {110143},
doi = {10.1016/j.celrep.2021.110143}
}
MLA
Cite this
MLA Copy
Joyce, M. Gordon, et al. “SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.” Cell Reports, vol. 37, no. 12, Dec. 2021, p. 110143. https://doi.org/10.1016/j.celrep.2021.110143.